Reading view
Why AI Alignment Failure Is Structural: Learned Human Interaction Structures and AGI as an Endogenous Evolutionary Shock
ISLA: A U-Net for MRI-based acute ischemic stroke lesion segmentation with deep supervision, attention, domain adaptation, and ensemble learning
Focus, Merge, Rank: Improved Question Answering Based on Semi-structured Knowledge Bases
Aligning Trustworthy AI with Democracy: A Dual Taxonomy of Opportunities and Risks
Microsoft announces glut of new data centers but says it won’t let your electricity bill go up
Google Introduces Conductor, a Context-Driven Development Extension for Gemini CLI

Google has released Conductor, a new preview extension for Gemini CLI that introduces a structured, context-driven approach to AI-assisted software development. The extension is designed to address a common limitation of chat-based coding tools: the loss of project context across sessions.
By Robert KrzaczyńskiConSensus: Multi-Agent Collaboration for Multimodal Sensing
A Large-Scale Study on the Development and Issues of Multi-Agent AI Systems
app.build: A Production Framework for Scaling Agentic Prompt-to-App Generation with Environment Scaffolding
Key Information Influencing Patient Decision-Making About AI in Health Care: Survey Experiment Study
FACTS Benchmark Suite Introduced to Evaluate Factual Accuracy of Large Language Models

A new industry benchmark aimed at systematically evaluating the factual accuracy of LLMs has been released with the launch of the FACTS Benchmark Suite. Developed by the FACTS team in collaboration with Kaggle, the suite expands earlier work on factual grounding and introduces a broader, multi-dimensional framework for measuring how reliably language models produce factually correct responses.
By Robert KrzaczyńskiInterpretable inflammation landscape of circulating immune cells
Nature Medicine, Published online: 12 January 2026; doi:10.1038/s41591-025-04126-3
Including data from 1,047 patients across 19 inflammatory diseases, a new atlas presents a comprehensive model of inflammation in circulating immune cells.The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm
Benchmarking LLM-based Agents for Single-cell Omics Analysis
Opinion: The NIH has lost its scientific integrity. So we left
We are National Institutes of Health scientists and administrators with more than 50 years of collective civil service.
Or, more accurately, we were NIH scientists and administrators.


© Adobe
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.
PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y
In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.